Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by SpringWorks Therapeutics, Inc.

< Previous 1 2 Next >
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Tickers SWTX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.